Market Overview

First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH

Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG) announced Saturday that results from an ad hoc
analysis of a subset of subjects with higher-risk myelodysplastic
syndrome (MDS) from two ongoing phase I/II studies of oral epigenetic
agent CC-486 (oral azacitidine) were presented at the American Society
of Hematology annual meeting in New Orleans, La.#ASH13

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free